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Peripheral neuropathy in ALS: 
phenotype association
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a 
rare and progressive neurodegenerative 
disease mainly affecting upper and lower 
motor neurons but also causing multi-
system involvement, in particular, associ-
ated with cognitive changes. Minor sensory 
fibre dysfunction has been described in the 
past1 and confirmed in recent studies.2 In 
a multicentre study investigating a popula-
tion of 88 patients with ALS, the ESTEEM 
group (a European Telematic Project for 
quality assurance within Clinical Neuro-
physiology) reported sensory polyneurop-
athy (PNP) in 12.5% of the patients, not 
influenced by age, disease duration and 
onset region.
In this study, we aimed to readdress 
prevalence of and risk factors for PNP in a 
larger population of patients with ALS. A 
large number of variables, including gene 
mutations, were assessed.
METHODS
We prospectively followed up patients 
with ALS in Lisbon (January 2015–
January 2018) consecutively enrolled 
into the OnWebDuals register3 to test the 
influence of clinical features and genotype 
on PNP prevalence. We included patients 
older than 18, with possible, probable or 
definite ALS according to the revised El 
Escorial criteria, and in line with the Awaji 
electrophysiological guidelines. Patients 
with known PNP, marked lower limb 
oedema, monoclonal gammopathy and 
those with incomplete neurophysiological 
examination were excluded. Age, gender, 
onset region, disease duration, weight 
loss before diagnosis (>10%), history 
of diabetes or cancer, previous chemo-
therapy or contact with neurotoxic agents, 
as well as SOD1 and C9orf72 mutations 
were recorded. Disease duration was 
defined as the time between the onset of 
muscle weakness and the neurophysiolog-
ical investigation, which was performed 
at diagnosis or during confirmatory eval-
uation for patients referred from other 
centres.
The study cohort underwent stan-
dardised nerve conduction studies as part 
of the assessment protocol. Motor conduc-
tion studies included bilateral peroneal 
and right ulnar nerves (distal latency and 
velocities), including F- waves (latency and 
persistence). Sensory action nerve poten-
tials (SNAPs) were recorded from peroneal 
nerves (distal leg, dorsum pedis) bilater-
ally (conduction velocity and amplitude), 
if one or both were abnormal additional 
SNAPs from sural nerves were recorded 
bilaterally (sura, behind the lateral malle-
olus). Stimulation and recording were 
performed through surface electrodes, 
and skin temperature was kept above 
30°C. SNAP amplitude<mean+2.5 SD 
(compared with age and gender- matched 
subjects from a historical control group) 
was accepted as abnormal. PNP was 
defined by the presence of one or two 
abnormal SNAPs from the peroneal nerves 
plus one or two abnormal SNAPs from 
the sural nerves. As established by Awaji 
guidelines, the presence of a mild PNP 
should not exclude the diagnosis of ALS, 
taking into account the clinical presenta-
tion and the full set of neurophysiological 
abnormalities.4 Patients with ALS with 
neurophysiological signs of neuropathy 
were grouped in group 2 (G2) and the 
remaining in group 1 (G1).
Mann- Whitney U test and χ2 or Fisher 
exact test were used to study differences 
between groups for continuous and cate-
gorical variables, respectively. Logistic 
regression analysis was applied to identify 
independent predictors for PNP (binary 
dependent variable). A p value of <0.05 
was considered as significant.
RESULTS
We included 339 patients with ALS, 
191 men (56.3%), with spinal (n=243, 
71.7%), bulbar (n=75, 22.1%), respi-
ratory (n=8, 2.4%), axial (n=6, 1.8%), 
cognitive (n=5, 1.5%) and generalised 
onset (n=2, 0.6%). Clinical and neuro-
physiological data were complete for 
every patient, while SOD1 and C9Orf72 
mutations were tested in 130 and 233 
patients, respectively.
From the total study population, 29 
patients had PNP according to the defini-
tion described earlier (8.6%, G2) vs 310 
patients without (91.4%, G1). SNAPs in 
all patients in G2 showed with mild or 
moderate amplitude reduction; sensory 
conduction velocity was borderline in 
19 patients and slightly reduced in 10. 
No patient was symptomatic for the 
neuropathy.
All demographic variables (table 1) 
were similar between groups (p>0.05) 
except for gender, age and frequency 
of respiratory onset. G2 was charac-
terised by a higher percentage of men 
(54.5% G1 vs 75.9% G2, p=0.027), older 
age (61.00±13.5 G1 vs 67.31±13.3 G2, 
p=0.01) and more frequent respiratory 
onset (p=0.024).
Logistic regression, including the all 
the variables defined in the Methods 
section, confirmed that age (p=0.014), 
gender (p=0.024) and respiratory onset 
(p=0.037) were independent predictors 
for PNP. Regarding age, a single addi-
tional year increased the risk of PNP by 
1.044 (CI 1.009 to 1.08); female gender 
decreased the risk of PNP by 0.644 (CI 
0.145 to 0.874); and respiratory onset 
increased the risk of PNP by 5.4 (CI 1.108 
to 26.156).
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Table 1 Demographic characteristics of the total population and of both groups (G1, no PNP 
and G2, with PNP)
Population G1 (no PNP) G2 (with PNP) P value*
Number of patients 339 310 (91.4%) 29 (8.6%)
Gender (men), n (%) 191 (56.3) 169 (54.5) 22 (75.9) 0.027*
Onset age (years) 61.54±13.5 61.00±13.5 67.31±13.3 0.01*
Disease duration (months) 21.03±30.6 21.18±31.3 19.47±20.9 0.86
Onset form, n (%)
  Spinal 243 (71.7) 223 (71.9) 20 (69.0) 0.83
  Bulbar 75 (22.1) 70 (22.6) 5 (17.2) 0.64
  Respiratory 8 (2.4) 5 (1.6) 3 (10.3) 0.024*
  Axial 6 (1.8) 5 (1.6) 1 (3.4) 0.418
  Dyscognition 5 (1.5) 5 (1.6) 0 1
  Generalised 2 (0.6) 2 (0.6) 0 1
Weight loss (yes), n (%) 53 (15.6) 51 (16.5) 2 (6.9) 0.28
Diabetes (yes), n (%) 39 (11.5) 35 (11.3) 4 (13.8) 0.76
Cancer (yes), n (%) 32 (9.4) 28 (9) 4 (13.8) 0.34
Chemotherapy and/or neurotoxic (yes), n (%) 8 (2.4) 7 (2.3) 1 (3.4) 0.52
SOD1 (yes), n (%) 2/130 2/119 0/11 1
C9orf72 (yes), n (%) 18/233 17/214 1/19 1
*P significant for <0.05.
ALS, amyotrophic lateral sclerosis; PNP, polyneuropathy; SNAPs, sensory action nerve potentials.
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DISCUSSION
PNP was found in 8.6% of our patients 
with ALS, similarly to previous publica-
tions.5 The slightly lower rate observed in 
our study can derive from not accepting 
a slower conduction velocity with normal 
SNAP amplitude as a marker of PNP, 
since patients with ALS tend to have cold 
extremities, and it is not possible to assure 
normal velocity of the action potential 
propagation along the axon by normal-
ising skin temperature.
History of diabetes, weight loss at diag-
nosis, cancer, chemotherapy or SOD1 and 
C9orf72 HRE mutations were not associ-
ated with PNP. However, PNP was more 
frequent in older men and, most strikingly, 
in patients with respiratory symptom 
onset. Many possible reasons underlying 
this association can be hypothesised, 
namely, hypercatabolic status and nutri-
tional factors, as well as PNP being part 
of this specific phenotype. We speculate 
that uncompensated peripheral hypoxia 
could cause peripheral nerve injury in this 
group of patients, as reported in diabetes, 
respiratory diseases and critical illness 
neuropathy.
Patients with respiratory onset were 
immediately adapted to non- invasive 
ventilation (NIV). One limitation of our 
study is that we did not perform follow- up 
measurements to assess if this intervention 
modified nerve conduction.
Further limitations of our study are the 
small number of patients presenting with 
respiratory onset, lack of genetic testing in 
some patients and of detailed information 
about the nutritional status and neuro-
physiological follow- up examinations. 
We present, however, the most complete 
evaluation of risk factors for PNP in ALS, 
specifically by including genetic findings 
and precise phenotypical characterisation, 
together with standardised neurophysio-
logical data.
We conclude that older men with 
respiratory- onset ALS have a higher risk 
of PNP. Follow- up studies of these patients 
on NIV would be necessary to understand 
the possible role of hypoxia in causing 
peripheral nerve dysfunction.
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